CA3192684A1 - Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) - Google Patents
Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)Info
- Publication number
- CA3192684A1 CA3192684A1 CA3192684A CA3192684A CA3192684A1 CA 3192684 A1 CA3192684 A1 CA 3192684A1 CA 3192684 A CA3192684 A CA 3192684A CA 3192684 A CA3192684 A CA 3192684A CA 3192684 A1 CA3192684 A1 CA 3192684A1
- Authority
- CA
- Canada
- Prior art keywords
- cltx
- dosing
- cca
- blood
- period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063080165P | 2020-09-18 | 2020-09-18 | |
| US63/080,165 | 2020-09-18 | ||
| US202163159397P | 2021-03-10 | 2021-03-10 | |
| US63/159,397 | 2021-03-10 | ||
| PCT/US2021/050677 WO2022060987A1 (en) | 2020-09-18 | 2021-09-16 | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3192684A1 true CA3192684A1 (en) | 2022-03-24 |
Family
ID=78087574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3192684A Pending CA3192684A1 (en) | 2020-09-18 | 2021-09-16 | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220087961A1 (https=) |
| EP (1) | EP4213829A1 (https=) |
| JP (1) | JP2023542932A (https=) |
| KR (1) | KR20230112609A (https=) |
| AU (1) | AU2021343475A1 (https=) |
| CA (1) | CA3192684A1 (https=) |
| IL (1) | IL301409A (https=) |
| MX (1) | MX2023003129A (https=) |
| TW (1) | TW202227046A (https=) |
| WO (1) | WO2022060987A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230106582A (ko) | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
| EP4698162A1 (en) * | 2023-04-21 | 2026-02-25 | Calcilytix Therapeutics, Inc. | Treatment of hypoparathyroidism using triphenyl calcilytic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407097A (pt) * | 2003-04-23 | 2006-01-24 | Japan Tobacco Inc | Antagonista do casr |
| KR20230106582A (ko) * | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
-
2021
- 2021-09-16 AU AU2021343475A patent/AU2021343475A1/en active Pending
- 2021-09-16 JP JP2023518198A patent/JP2023542932A/ja active Pending
- 2021-09-16 CA CA3192684A patent/CA3192684A1/en active Pending
- 2021-09-16 WO PCT/US2021/050677 patent/WO2022060987A1/en not_active Ceased
- 2021-09-16 US US17/477,198 patent/US20220087961A1/en active Pending
- 2021-09-16 MX MX2023003129A patent/MX2023003129A/es unknown
- 2021-09-16 EP EP21790717.9A patent/EP4213829A1/en active Pending
- 2021-09-16 IL IL301409A patent/IL301409A/en unknown
- 2021-09-16 KR KR1020237012476A patent/KR20230112609A/ko active Pending
- 2021-09-17 TW TW110134985A patent/TW202227046A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023542932A (ja) | 2023-10-12 |
| KR20230112609A (ko) | 2023-07-27 |
| TW202227046A (zh) | 2022-07-16 |
| WO2022060987A1 (en) | 2022-03-24 |
| IL301409A (en) | 2023-05-01 |
| EP4213829A1 (en) | 2023-07-26 |
| AU2021343475A9 (en) | 2024-05-02 |
| US20220087961A1 (en) | 2022-03-24 |
| MX2023003129A (es) | 2023-08-04 |
| AU2021343475A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haffner et al. | Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia | |
| US20140194484A1 (en) | Method of Treating Cachexia and Sarcopenia | |
| Christensson et al. | Hypercalcemia and primary hyperparathyroidism: prevalence in patients receiving thiazides as detected in a health screen | |
| KR100445946B1 (ko) | 폐고혈압 치료법 | |
| US20220323445A1 (en) | Reducing immunogenicity to pegloticase | |
| Palmer | A physiologic-based approach to the evaluation of a patient with hyperkalemia | |
| PT2275086E (pt) | Formulação de volume reduzido de acetato de glatirâmero e métodos de administração | |
| Bacchetta et al. | X-linked hypophosphatemia and burosumab: practical clinical points from the French experience | |
| US20220087961A1 (en) | Treatment methods of triphenyl calcilytic compounds | |
| O'Loughlin et al. | IRON NOF trial: IV iron for anaemic patients with femoral fracture | |
| RU2576511C2 (ru) | Пероральная терапия недостаточности витамина в12 | |
| JP2002518323A (ja) | 選択的エストロゲン受容体修飾物質と上皮小体ホルモンとを含む治療用組合わせ物 | |
| Pandey et al. | Use of 2MD, a novel oral calcitriol analog, in hemodialysis patients with secondary hyperparathyroidism | |
| JP2002518326A (ja) | 筋骨格脆性治療のための（選択的）エストロゲンレセプターモジュレーター（ｓｅｒｍ）及び成長ホルモン分泌促進剤（ｇｈｓ）の治療用組合せ | |
| CN116916907A (zh) | 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物 | |
| US12208092B2 (en) | Compositions and methods for administering paltusotine to patients with hepatic impairment | |
| EP1280555B1 (en) | Pharmaceutical composition comprising furosemide and conivaptan for the treatment of congestive heart failure | |
| US20240423961A1 (en) | 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones | |
| US20210085711A1 (en) | Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease | |
| US20250222003A1 (en) | Pharmaceutical composition for treating solid tumors | |
| TW202506101A (zh) | 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療 | |
| Sato et al. | Hypomagnesemia Causing Convulsions in a Patient Taking a Proton Pump Inhibitor: A Case Report | |
| WO2026032924A1 (en) | Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough | |
| Matsumoto et al. | Hypercalcemia with the Oral Administration of Active Vitamin D3 and Chinese Herbal Medicine | |
| Moretz | Drug Class Literature Scan: Iron Replacement, Oral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250908 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250908 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250909 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250909 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250909 |